# Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

> **NCT02885181** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 83 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GS-9876
- **DRUG:** Filgotinib
- **DRUG:** GS-9876 placebo
- **DRUG:** Filgotinib placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02885181
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-21
- **Primary completion:** 2017-08-22
- **Final completion:** 2017-09-20
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02885181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02885181, "Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02885181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*